{"id":790,"date":"2016-02-08T10:44:21","date_gmt":"2016-02-08T05:14:21","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=790"},"modified":"2025-05-05T16:57:58","modified_gmt":"2025-05-05T11:27:58","slug":"pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","title":{"rendered":"PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2016"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2fe03293e27\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2fe03293e27\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#DelveInsight_has_made_strong_presence_in_Oncology_market_with_100_Reports_on_Oncology_based_Indications_Mechanism_of_Action_MOA_DelveInsight_Report_PD-1_and_PD-L_1_inhibitors_%E2%80%93_Competitive_Landscape_Pipeline_and_Market_Analysis_2016_has_received_great_response_and_feedback_from_clients\" >DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications &amp; Mechanism of Action (MOA).\u00a0DelveInsight Report,\u00a0PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback\u00a0from clients.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#PD-1and_PDL-1_is_the_next_targeted_agents_in_Oncology_These_therapies_have_the_enormous_potential_to_treat_cancer_and_have_an_excellent_response_in_the_increasing_number_of_patients_Many_experts_say_that_out_of_all_of_the_therapies_PD-1PD-L1_inhibitors_look_to_be_the_most_promising_in_treating_cancer\" >PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1\/PD-L1 inhibitors look to be the most promising in treating cancer.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Reports_Highlights\" >Reports Highlights:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#PD-1_and_PD-L1_Inhibitors_Therapy_Pipeline_scenario\" >PD-1 and PD-L1 Inhibitors\u00a0Therapy Pipeline scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Collaborations_partnering_deals\" >Collaborations &amp; partnering deals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Current_Prominent_Research_Areas_and_Key_Players\" >Current Prominent Research Areas and Key Players<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Pipeline_product_profiles_PD-1_and_PD-L1_Inhibitors_Technologies\" >Pipeline product profiles\u00a0PD-1 and PD-L1 Inhibitors\u00a0Technologies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Market_Drivers_and_Barriers\" >Market Drivers and Barriers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#Report_Coverage\" >Report Coverage:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#40_products_30_companies_and_15_different_technologies\" >40+\u00a0products,\u00a030+ companies and 15+ different technologies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#PD-1PDL-1_Inhibitors_report_provides_the_analysis_on_the_worldwide_therapeutic_market_of_PD-1_and_PD-L1_inhibitors_In_addition_the_report_provides_the_development_of_combinations_therapies_with_Immune-check_point_Inhibitors_PD-1_and_PD-L1_along_with_the_information_on_ongoing_collaborations_for_the_development_of_combinations_regimens\" >PD-1\/PDL-1 Inhibitors report\u00a0provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#_PD-1PDL-1_Inhibitors_report_report_covers_the_therapeutics_assessment_of_pipeline_molecules_by_mechanism_of_action_MoA_route_of_administration_RoA_molecule_type_along_with_latest_updates_The_reports_also_cover_Commercial_Aspects_such_as_the_Current_and_Future_Market_market_drivers_and_barriers_followed_by_SWOT_Analysis\" >\u00a0PD-1\/PDL-1 Inhibitors report\u00a0report covers the\u00a0therapeutics assessment\u00a0of pipeline molecules by\u00a0mechanism of action (MoA),\u00a0route of administration\u00a0(RoA),\u00a0molecule type, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market,\u00a0market drivers and barriers followed by SWOT Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#The_Reports_will_help_you_to_identify_emerging_players_with_potentially_strong_product_information_licensing_opportunities_and_helps_you_to_create_effective_counter-strategies_to_gain_competitive_advantage\" >The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#DelveInsight_is_offering_the_Report_at_a_price_of_USD_2950_as_a_single_user_license_USD_5900_as_a_site_license_andUSD_8850_as_a_GlobalEnterprise_License\" >DelveInsight is offering the Report at a price of\u00a0USD\u00a02,950\u00a0as a single user license,\u00a0USD 5,900\u00a0as a site license andUSD 8,850\u00a0as a Global\/Enterprise License.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#For_more_information_mail_us_at_infodelveinsightcom\" >For more information mail us at\u00a0info@delveinsight.com<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\/#About_Us_DelveInsight_is_a_leading_Business_Consulting_and_Market_Research_Firm_We_help_our_clients_to_find_answers_relevant_to_their_business_facilitating_decision-making_identify_potential_market_opportunities_competitor_assessments_and_business_environmental_assessment_In_addition_to_this_DelveInsight_also_deals_in_providing_custom_research_services_in_coherence_with_interest_area_of_the_clients\" >About Us: \nDelveInsight is a leading Business Consulting and Market Research Firm.\u00a0 We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/a><\/li><\/ul><\/nav><\/div>\n<h6><span class=\"ez-toc-section\" id=\"DelveInsight_has_made_strong_presence_in_Oncology_market_with_100_Reports_on_Oncology_based_Indications_Mechanism_of_Action_MOA_DelveInsight_Report_PD-1_and_PD-L_1_inhibitors_%E2%80%93_Competitive_Landscape_Pipeline_and_Market_Analysis_2016_has_received_great_response_and_feedback_from_clients\"><\/span><strong><em>DelveInsight<\/em><\/strong>\u00a0has made strong presence in Oncology market with\u00a0<strong>100+\u00a0<\/strong>Reports on Oncology based\u00a0<strong>Indications &amp; Mechanism of Action (MOA).\u00a0<\/strong>DelveInsight Report,\u00a0<strong><em>PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2016 <\/em><\/strong>has received great response and feedback\u00a0from clients.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"PD-1and_PDL-1_is_the_next_targeted_agents_in_Oncology_These_therapies_have_the_enormous_potential_to_treat_cancer_and_have_an_excellent_response_in_the_increasing_number_of_patients_Many_experts_say_that_out_of_all_of_the_therapies_PD-1PD-L1_inhibitors_look_to_be_the_most_promising_in_treating_cancer\"><\/span>PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1\/PD-L1 inhibitors look to be the most promising in treating cancer.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"Reports_Highlights\"><\/span>Reports Highlights:<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<ul>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"PD-1_and_PD-L1_Inhibitors_Therapy_Pipeline_scenario\"><\/span><strong>PD-1 and PD-L1 Inhibitors\u00a0<\/strong>Therapy Pipeline scenario<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Collaborations_partnering_deals\"><\/span>Collaborations &amp; partnering deals<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Current_Prominent_Research_Areas_and_Key_Players\"><\/span>Current Prominent Research Areas and Key Players<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Pipeline_product_profiles_PD-1_and_PD-L1_Inhibitors_Technologies\"><\/span>Pipeline product profiles\u00a0<strong>PD-1 and PD-L1 Inhibitors\u00a0<\/strong>Technologies<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Market_Drivers_and_Barriers\"><\/span>Market Drivers and Barriers<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<\/ul>\n<h6><span class=\"ez-toc-section\" id=\"Report_Coverage\"><\/span>Report Coverage:<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"40_products_30_companies_and_15_different_technologies\"><\/span>40+\u00a0products,\u00a030+ companies and 15+ different technologies<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"PD-1PDL-1_Inhibitors_report_provides_the_analysis_on_the_worldwide_therapeutic_market_of_PD-1_and_PD-L1_inhibitors_In_addition_the_report_provides_the_development_of_combinations_therapies_with_Immune-check_point_Inhibitors_PD-1_and_PD-L1_along_with_the_information_on_ongoing_collaborations_for_the_development_of_combinations_regimens\"><\/span><strong>PD-1\/PDL-1 Inhibitors report<\/strong>\u00a0provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"_PD-1PDL-1_Inhibitors_report_report_covers_the_therapeutics_assessment_of_pipeline_molecules_by_mechanism_of_action_MoA_route_of_administration_RoA_molecule_type_along_with_latest_updates_The_reports_also_cover_Commercial_Aspects_such_as_the_Current_and_Future_Market_market_drivers_and_barriers_followed_by_SWOT_Analysis\"><\/span><strong>\u00a0<\/strong><strong>PD-1\/PDL-1 Inhibitors report\u00a0<\/strong>report covers the\u00a0<strong>therapeutics assessment<\/strong>\u00a0of pipeline molecules by\u00a0<strong>mechanism of action (MoA),<\/strong>\u00a0<strong>route of administration<\/strong>\u00a0(RoA),\u00a0<strong>molecule type<\/strong>, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market,\u00a0market drivers and barriers followed by SWOT Analysis<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"The_Reports_will_help_you_to_identify_emerging_players_with_potentially_strong_product_information_licensing_opportunities_and_helps_you_to_create_effective_counter-strategies_to_gain_competitive_advantage\"><\/span>The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"DelveInsight_is_offering_the_Report_at_a_price_of_USD_2950_as_a_single_user_license_USD_5900_as_a_site_license_andUSD_8850_as_a_GlobalEnterprise_License\"><\/span>DelveInsight is offering the Report at a price of\u00a0<strong><em>USD\u00a02,950<\/em><\/strong>\u00a0as a single user license,\u00a0<strong><em>USD 5,900\u00a0<\/em><\/strong>as a site license and<strong><em>USD 8,850<\/em><\/strong>\u00a0as a Global\/Enterprise License.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"For_more_information_mail_us_at_infodelveinsightcom\"><\/span><strong>For more information mail us at<\/strong><strong>\u00a0<\/strong><strong>info@delveinsight.com<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"About_Us_DelveInsight_is_a_leading_Business_Consulting_and_Market_Research_Firm_We_help_our_clients_to_find_answers_relevant_to_their_business_facilitating_decision-making_identify_potential_market_opportunities_competitor_assessments_and_business_environmental_assessment_In_addition_to_this_DelveInsight_also_deals_in_providing_custom_research_services_in_coherence_with_interest_area_of_the_clients\"><\/span><strong>About Us:<\/strong><br \/>\nDelveInsight is a leading Business Consulting and Market Research Firm.\u00a0 We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><\/h6>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications &amp; Mechanism of Action (MOA).\u00a0DelveInsight Report,\u00a0PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback\u00a0from clients. PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,173,180,204,216,356,386,427,479],"industry":[17225],"therapeutic_areas":[17227,17228,17234],"class_list":["post-790","post","type-post","status-publish","format-standard","hentry","category-articles","tag-business-consultant","tag-collaborations","tag-competitive-landscape","tag-delveinsight","tag-drug","tag-licensing-opportunities","tag-market-trends","tag-oncology","tag-pipeline-coverage","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PD-1 and PD-L 1 inhibitors -Competitive Landscape and Market Analysis<\/title>\n<meta name=\"description\" content=\"DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications &amp; Mechanism of Action (MOA)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PD-1 and PD-L 1 inhibitors -Competitive Landscape and Market Analysis\" \/>\n<meta property=\"og:description\" content=\"DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications &amp; Mechanism of Action (MOA)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-02-08T05:14:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:27:58+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PD-1 and PD-L 1 inhibitors -Competitive Landscape and Market Analysis","description":"DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications & Mechanism of Action (MOA)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","og_locale":"en_US","og_type":"article","og_title":"PD-1 and PD-L 1 inhibitors -Competitive Landscape and Market Analysis","og_description":"DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications & Mechanism of Action (MOA)...","og_url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-02-08T05:14:21+00:00","article_modified_time":"2025-05-05T11:27:58+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report","name":"PD-1 and PD-L 1 inhibitors -Competitive Landscape and Market Analysis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2016-02-08T05:14:21+00:00","dateModified":"2025-05-05T11:27:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight\u00a0has made strong presence in Oncology market with\u00a0100+\u00a0Reports on Oncology based\u00a0Indications & Mechanism of Action (MOA)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline coverage<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Drug<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Pipeline coverage<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 8, 2016","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Feb 8, 2016 10:44 am","modified":"Updated on May 5, 2025 4:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/790\/revisions"}],"predecessor-version":[{"id":31658,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/790\/revisions\/31658"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=790"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=790"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}